Regenerative Medicine and Stem Cells Technologies

The ultimate goal of periodontal disease treatment is the reorganization of functional tissue that can regenerate lost periodontal tissue. Regeneration of periodontal tissues is clinically possible by using autogenic transplantation of MSCs.

In pursuit of a novel tool for the research and treatment of celiac disease, scientists at the Mucosal Immunology and Biology Research Center (MIBRC) at Massachusetts General Hospital (MGH) have validated the use of intestinal organoids.

Researchers have developed a method that could drastically accelerate the search for new drugs to treat mental health disorders such as schizophrenia.

University of Massachusetts Lowell researches say they have discovered a use for eggs that goes far beyond simple cooking and eating.

A discovery of how stem cells are protected from viruses could inform the development of therapies for use in medicine, research suggests.

Scientists at the Morgridge Institute for Research are working toward a dream of creating artery banks similar to blood banks common today with readily-available material to replace diseased arteries during surgery.

The human body has powerful healing abilities. But treating brain disorders is no easy task, as brain cells—neurons—have limited ability to regenerate. Nonetheless, stem cells are a form of natural backup, a vestige of our days as still-developing embryos.

Our hair, skin and eyes are colored by a pigment called melanin, which is produced by pigment cells called melanocytes.

Researchers at Karolinska Institutet in Sweden have developed a stem cell-based model to study the resilience and vulnerability of neurons in the neurodegenerative disease ALS. The results are published in the journal Stem Cell Reports, and could aid in the identification of new genetic targets for treatments protecting sensitive neurons.

Novartis Chief Executive Officer Vas Narasimhan is excited about the company’s progress through the first half of 2019 and expects that momentum to continue with a “catalyst-rich” second half of the year.